MIN 101

Drug Profile

MIN 101

Alternative Names: CYR-101; MIN-101; MT-210

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Minerva Neurosciences
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists; Sigma-2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia

Most Recent Events

  • 20 Jan 2017 Additional efficacy data from a phase IIb trial in Schizophrenia released by Minerva Neurosciences
  • 01 Nov 2016 Phase-I clinical trials in Schizophrenia (In volunteers) in Ireland (PO, Controlled-release) (NCT03038646)
  • 26 Oct 2016 Efficacy and adverse events data from the extension period of a phase IIb trial in Schizophrenia released by Minerva Neurosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top